|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|2145813||1088829||2012||12 صفحه PDF||سفارش دهید||دانلود رایگان|
The genetic and epigenetic material originating from tumour that can be found in body fluids of individuals with cancer harbours tumour-specific alterations and represents an attractive target for biomarker discovery. Epigenetic changes (DNA methylation, histone modifications and non-coding RNAs) are present ubiquitously in virtually all types of human malignancies and may appear in early cancer development, and thus they provide particularly attractive markers with broad applications in diagnostics. In addition, because changes in the epigenome may constitute a signature of specific exposure to certain risk factors, they have the potential to serve as highly specific biomarkers for risk assessment. While reliable detection of cancer-specific epigenetic changes has proven to be technically challenging, a substantial progress has been made in developing the methodologies that allow an efficient and sensitive detection of epigenomic changes using the material originating from body fluids. In this review we discuss the application of epigenomics as a tool for biomarker research, with the focus on the analysis of DNA methylation in biofluids.
► Validation of epigenetic biomarkers in clinics and epidemiology is in its infancy.
► Recent progress allows reliable detection of cancer-specific epigenetic changes in body fluids.
► New advances in epigenomics hold promise for generation of powerful cancer biomarkers.
Journal: Molecular Oncology - Volume 6, Issue 6, December 2012, Pages 704–715